# Johns Hopkins HIV Clinical Cohort

> **NIH NIH U01** · JOHNS HOPKINS UNIVERSITY · 2022 · $1,470,508

## Abstract

The Johns Hopkins HIV Clinical Cohort (JHHCC) has been a resource since 1989 for longitudinal
research on the risk factors, treatment and clinical outcomes of persons with HIV (PWH). The Baltimore
region has overlapping epidemics of HIV infection and substance use, predominantly heroin and cocaine
use, and much of our research has focused in this population, with the advantage of directly comparing
those who use substances with a non-use population from the same geographic and socioeconomic
catchment areas of the region. Our cohort is predominantly African-American with a high proportion of
women, providing a needed window into these epidemics in these often understudied populations.
Highly-effective antiretroviral therapy (ART) has markedly improved survival; the median age of the
JHHCC cohort is 54 years with an expected life-expectancy of 20-30 years. New federal initiatives have
a goal of >90% of PWH in HIV care, so that data to better understand and overcome the challenges to
long-term HIV care are particularly relevant to the contemporary epidemic. Our current Aims build upon
our strengths in longitudinal research, focusing on the chronically-infected patient population on long-
term ART. Non-communicable diseases (NCD) appear to be occurring at higher rates and at earlier
ages than expected, even in those who are virally suppressed. We and others have shown that
substance use is a barrier to achieving the outcomes of the HIV Care Continuum, and increases the risk
of comorbidity and mortality in HIV. Our first Aim is to characterize the extended clinical course of PWH
in contemporary HIV care, evaluating the associations of opioid and other substance use and its
treatment with the HIV Care Continuum, NCD morbidity and mortality in those aging with HIV. Another
focus of the JHHCC has been viral hepatitis co-infection, particularly hepatitis C (HCV), a comorbidity
that is prevalent in 40% of our patients, principally because of IDU. Although we are now effectively
treating HCV, challenges remain in curing those who use substances and in those who are treated, liver
fibrosis is common and the future risk of cirrhosis, steatosis and hepatic cancer is unclear, as well as
the risk of re-infection. Our second Aim will focus on HCV treatment and the rates and risks of these
adverse liver outcomes and re-infection in those who have been treated. Finally, the JHHCC has a
proven history of highly productive collaboration, with over 500 publications, half of which are with
multisite collaborations. These include not only observational research, but translational studies of
pathogenesis, implementation science and clinical trials. Our third Aim is to enhance collaboration with
investigators who would benefit from the resources of the JHHCC, and especially as part of the
Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO).

## Key facts

- **NIH application ID:** 10356131
- **Project number:** 5U01DA036935-08
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** RICHARD Douglas MOORE
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,470,508
- **Award type:** 5
- **Project period:** 2014-07-01 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10356131

## Citation

> US National Institutes of Health, RePORTER application 10356131, Johns Hopkins HIV Clinical Cohort (5U01DA036935-08). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10356131. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*